SENTRY BIOPHARMA SERVICES INC

SENTRY BIOPHARMA SERVICES INC specializes in pharmaceutical manufacturing and biopharmaceutical process development, operating under NAICS 325412 for pharmaceutical preparation. The company provides end-to-end contract development and manufacturing services for sterile and non-sterile drug products, including formulation optimization, analytical method validation, aseptic processing, and regulatory-compliant production scaling. Their technical expertise lies in GMP compliance, batch record management, process validation, and quality control systems aligned with FDA 21 CFR Part 211 and ICH guidelines. Key differentiators include precision in lyophilization, biologics handling, and supply chain integrity for clinical and commercial-phase pharmaceuticals, with a focus on minimizing contamination risks and ensuring product stability under controlled environments. Award history does not provide sufficient detail to identify specific federal agencies or program relationships. Consequently, no definitive patterns of agency engagement can be inferred from available data. The company’s primary industry focus is pharmaceutical preparation, encompassing the synthesis, blending, encapsulation, and packaging of active pharmaceutical ingredients into final dosage forms. This vertical specialization positions SENTRY BIOPHARMA SERVICES INC as a niche provider for biopharmaceutical firms requiring compliant, scalable manufacturing support without in-house production capacity. Their market positioning emphasizes regulatory rigor, batch traceability, and cGMP adherence in support of both small-molecule and biologic drug candidates. SENTRY BIOPHARMA SERVICES INC is structured as a small business under the 2L entity classification and is headquartered in Indianapolis, Indiana. The company holds no active government certifications such as 8(a), HUBZone, or WOSB. Its geographic presence is centered in the Midwest, with operations tailored to serve regional and national biopharma clients requiring onshore, FDA-inspected manufacturing capabilities. The firm’s operational model prioritizes agility, quality assurance, and compliance-driven production in a highly regulated environment.